Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

I-Mab Major Shareholding Notification 2022

Jan 25, 2022

33048_mrq_2022-01-25_1a55781c-87a8-4ebb-b2b4-2b5ec8db9757.zip

Major Shareholding Notification

Open in viewer

Opens in your device viewer

SC 13G/A 1 tm224403d2_sc13ga.htm SC 13G/A

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

I-MAB

(Name of Issuer)

Ordinary Shares, par value $0.0001**

American Depositary Shares

(Title of Class of Securities)

44975P103 **

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

  • The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 2 of 17 Pages

1 NAMES OF REPORTING PERSONS IBC Investment Seven Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 3,641,554
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 3,641,554
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,641,554
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.0% 1
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

1 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022.

Field: Page; Sequence: 2

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 3 of 17 Pages

1 NAMES OF REPORTING PERSONS CBC SPVII LIMITED
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 5,574,560
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 5,574,560
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,574,560
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.0% 2
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

2 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022.

Field: Page; Sequence: 3

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 4 of 17 Pages

1 NAMES OF REPORTING PERSONS CBC Investment I-Mab Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 11,784,164
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 11,784,164
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,784,164
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.4% 3
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

3 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022.

Field: Page; Sequence: 4

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 5 of 17 Pages

1 NAMES OF REPORTING PERSONS C-Bridge II Investment Ten Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 2,369,546
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 2,369,546
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,369,546
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.3% 4
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

4 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 5

Field: /Page

Field: Split-Segment; Name: 1

CUSIP No. 44975P103 SCHEDULE 13G Page 6 of 17 Pages

1 NAMES OF REPORTING PERSONS Everest Medicines Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 6,078,571
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 6,078,571
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,078,571
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.3% 5
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

5 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 6

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 7 of 17 Pages

1 NAMES OF REPORTING PERSONS C-Bridge II Investment Thirteen Limited
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 0
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.0%
12 TYPE OF REPORTING PERSON CO

Field: Page; Sequence: 7

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 8 of 17 Pages

1 NAMES OF REPORTING PERSONS C-Bridge Healthcare Fund II, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 14,153,710
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 14,153,710
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 14,153,710
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.7% 6
12 TYPE OF REPORTING PERSON PN

Field: Rule-Page

Field: /Rule-Page

6 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 8

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 9 of 17 Pages

1 NAMES OF REPORTING PERSONS C-Bridge Healthcare Fund GP II, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 14,153,710
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 14,153,710
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 14,153,710
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.7% 7
12 TYPE OF REPORTING PERSON PN

Field: Rule-Page

Field: /Rule-Page

7 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 9

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 10 of 17 Pages

1 NAMES OF REPORTING PERSONS C-Bridge Capital GP, Ltd.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0
6 SHARED VOTING POWER 23,369,824
7 SOLE DISPOSITIVE POWER 0
8 SHARED DISPOSITIVE POWER 23,369,824
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 23,369,824
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES ¨
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12.7% 8
12 TYPE OF REPORTING PERSON CO

Field: Rule-Page

Field: /Rule-Page

8 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 10

Field: /Page

Field: Split-Segment; Name: 1

CUSIP No. 44975P103 SCHEDULE 13G Page 11 of 17 Pages

| 1 | NAMES
OF REPORTING PERSONS I-Bridge Healthcare Fund, L.P. |
| --- | --- |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x |
| 3 | SEC
USE ONLY |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Cayman Islands |

| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE
VOTING POWER 0 |
| --- | --- |
| 6 | SHARED
VOTING POWER 9,216,114 |
| 7 | SOLE
DISPOSITIVE POWER 0 |
| 8 | SHARED
DISPOSITIVE POWER 9,216,114 |

| 9 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,216,114 |
| --- | --- |
| 10 | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
| 11 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.0% 9 |
| 12 | TYPE
OF REPORTING PERSON PN |

Field: Rule-Page

Field: /Rule-Page

9 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 11

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 12 of 17 Pages

| 1 | NAMES
OF REPORTING PERSONS I-Bridge Healthcare GP, L.P. |
| --- | --- |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x |
| 3 | SEC
USE ONLY |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Cayman Islands |

| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE
VOTING POWER 0 |
| --- | --- |
| 6 | SHARED
VOTING POWER 9,216,114 |
| 7 | SOLE
DISPOSITIVE POWER 0 |
| 8 | SHARED
DISPOSITIVE POWER 9,216,114 |

| 9 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,216,114 |
| --- | --- |
| 10 | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
| 11 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.0% 10 |
| 12 | TYPE
OF REPORTING PERSON PN |

Field: Rule-Page

Field: /Rule-Page

10 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 12

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 13 of 17 Pages

| 1 | NAMES
OF REPORTING PERSONS I-Bridge Capital GP, Ltd. |
| --- | --- |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x |
| 3 | SEC
USE ONLY |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Cayman Islands |

| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE
VOTING POWER 0 |
| --- | --- |
| 6 | SHARED
VOTING POWER 9,216,114 |
| 7 | SOLE
DISPOSITIVE POWER 0 |
| 8 | SHARED
DISPOSITIVE POWER 9,216,114 |

| 9 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,216,114 |
| --- | --- |
| 10 | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
| 11 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.0% 11 |
| 12 | TYPE
OF REPORTING PERSON CO |

Field: Rule-Page

Field: /Rule-Page

11 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 13

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 14 of 17 Pages

| 1 | NAMES
OF REPORTING PERSONS Wei Fu |
| --- | --- |
| 2 | CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x |
| 3 | SEC
USE ONLY |
| 4 | CITIZENSHIP
OR PLACE OF ORGANIZATION Singapore |

| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | SOLE
VOTING POWER 0 |
| --- | --- |
| 6 | SHARED
VOTING POWER 29,448,395 |
| 7 | SOLE
DISPOSITIVE POWER 0 |
| 8 | SHARED
DISPOSITIVE POWER 29,448,395 |

| 9 | AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 29,448,395 |
| --- | --- |
| 10 | CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ |
| 11 | PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 16.0% 12 |
| 12 | TYPE
OF REPORTING PERSON IN |

Field: Rule-Page

Field: /Rule-Page

12 Based upon 183,826,753 ordinary shares of the Issuer reported to be outstanding as of December 31, 2021 in the Issuer’s Rule 424(b)(3) prospectus supplement, filed with the SEC on January 14, 2022 .

Field: Page; Sequence: 14

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 15 of 17 Pages

Item 1(a) Name of Issuer :

I-MAB (the “ Issuer ”)

Item 1(b) Address of Issuer’s Principal Executive Offices :

Suite 802, West Tower, OmniVision

88 Shangke Road, Pudong District

Shanghai, 201210

People’s Republic of China

Item 2(a) Name of Persons Filing :

This Amendment No.1 to the Schedule 13G is filed by and on behalf of:

  1. IBC Investment Seven Limited

  2. CBC SPVII LIMITED

  3. CBC Investment I-Mab Limited

  4. C-Bridge II Investment Ten Limited

  5. Everest Medicines Limited

  6. C-Bridge II Investment Thirteen Limited

  7. C-Bridge Healthcare Fund II, L.P.

  8. C-Bridge Healthcare Fund GP II, L.P.

  9. C-Bridge Capital GP, Ltd.

  10. I-Bridge Healthcare Fund, L.P.

  11. I-Bridge Healthcare GP, L.P.

  12. I-Bridge Capital GP, Ltd.

  13. Wei Fu

This statement on Schedule 13G relates to securities directly held by IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited, Everest Medicines Limited , and C-Bridge II Investment Thirteen Limited.

CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited and C-Bridge II Investment Thirteen Limited are controlled by C-Bridge Healthcare Fund II, L.P., whose general partner is C-Bridge Healthcare Fund GP II, L.P., and its general partner is C-Bridge Capital GP, Ltd.

CBC SPVII Limited and IBC Investment Seven Limited are controlled by I-Bridge Healthcare Fund, L.P., whose general partner is I-Bridge Healthcare GP, L.P., and its general partner is I-Bridge Capital GP, Ltd., which is indirectly controlled by C-Bridge Capital GP, Ltd.

Mr. Wei Fu is the sole director of C-Bridge Capital GP, Ltd.

Field: Page; Sequence: 15

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 16 of 17 Pages

Everest Medicines Limited is a public company listed on the Hong Kong Stock Exchange and controlled by funds which are under common control of the C-Bridge group, which, in turn, is controlled by Mr. Wei Fu.

C-Bridge Healthcare Fund II, L.P., C-Bridge Healthcare Fund GP II, L.P., C-Bridge Capital GP, Ltd., I-Bridge Healthcare Fund, L.P., I-Bridge Healthcare GP, L.P., I-Bridge Capital GP, Ltd., and Mr. Wei Fu may be deemed to beneficially own the securities of the Issuer owned by the entities which they control.

Item 2(b) Address of Principal Business Office or, If None, Residence

The business address of each reporting person is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Item 2(c) Citizenship

  1. IBC Investment Seven Limited: Hong Kong

  2. CBC SPVII LIMITED: Hong Kong

  3. CBC Investment I-Mab Limited: British Virgin Islands

  4. C-Bridge II Investment Ten Limited: British Virgin Islands

  5. Everest Medicines Limited: Cayman Islands

  6. C-Bridge II Investment Thirteen Limited: British Virgin Islands

  7. C-Bridge Healthcare Fund II, L.P.: Cayman Islands

  8. C-Bridge Healthcare Fund GP II, L.P.: Cayman Islands

  9. C-Bridge Capital GP, Ltd.: Cayman Islands

  10. I-Bridge Healthcare Fund, L.P.: Cayman Islands

  11. I-Bridge Healthcare GP, L.P.: Cayman Islands

  12. I-Bridge Capital GP, Ltd.: Cayman Islands

  13. Wei Fu: Singapore

Item 2(d) Title of Class of Securities :

Ordinary Shares, par value $0.0001

Item 2(e) CUSIP Number :

44975P103

Item 3. Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

Not applicable.

Item 4. Ownership

The information for each reporting person contained in rows 5-11 of the cover pages and Item 2(a) is incorporated herein by reference.

Field: Page; Sequence: 16

Field: /Page

CUSIP No. 44975P103 SCHEDULE 13G Page 17 of 17 Pages

Item 5. Ownership of Five Percent or Less of a Class

This Amendment No. 1 serves as an exit filing for C-Bridge II Investment Thirteen Limited which, as of the date of this filing, no longer beneficially owns any Ordinary Shares.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certifications

Not applicable.

Field: Page; Sequence: 17

Field: /Page

Field: Split-Segment; Name: 2

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 25, 2022

| IBC Investment
Seven Limited | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

CBC SPVII LIMITED
By: /s/
Wei Fu
Name: Wei FU
Title: Director

| CBC Investment
I-Mab Limited | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

| C-Bridge II Investment
Ten Limited | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

| Everest Medicines
Limited | |
| --- | --- |
| By: | /s/
Xiaofan Zhang |
| Name: | Xiaofan ZHANG |
| Title: | Director |

| C-Bridge II Investment
Thirteen Limited | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

Field: Page; Sequence: 18

Field: /Page

| C-Bridge Healthcare
Fund II, L.P. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Authorized Representative |

| C-Bridge Healthcare
Fund GP II, L.P. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Authorized Representative |

| C-Bridge Capital
GP, Ltd. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

| I-Bridge Healthcare
Fund, L.P. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Authorized Representative |

| I-Bridge Healthcare
GP, L.P. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Authorized Representative |

| I-Bridge Capital
GP, Ltd. | |
| --- | --- |
| By: | /s/
Wei Fu |
| Name: | Wei FU |
| Title: | Director |

Wei FU
By: /s/
Wei Fu

Field: Page; Sequence: 19; Options: Last

Field: /Page

More from I-Mab

Regulatory Filings 2026
Apr 22
Regulatory Filings 2026
Apr 7
Annual Report 2026
Apr 7
Director's Dealing 2026
Mar 25
Director's Dealing 2026
Mar 19
Director's Dealing 2026
Mar 19
Director's Dealing 2026
Mar 19
Director's Dealing 2026
Mar 19
Director's Dealing 2026
Mar 19
Director's Dealing 2026
Mar 19
View all filings →